LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Aktien・Novartis AG

Novartis AG

Open

116.34 0.69

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

115.54

Max

116.67

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.7B
Verkäufe	344M 12B
KGV Branchendurchschnitt	23.59 103.001
EPS	1.31
Gewinnspanne	22.178
EBITDA	4.7B

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+2.96 upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	818M 247B
Vorheriger Eröffnungskurs	115.65
Vorheriger Schlusskurs	116.34

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

115.28 / 117.16 Unterstützung & Widerstand

Novartis AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Aug. 2024, 09:47 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis Confirms Offer for Diagnostic Arm From Siemens Healthineers

18. Juli 2024, 05:58 UTC

Ergebnisse

Novartis Raises Profit Guidance as Key Drugs Boost Sales -- Update

18. Juli 2024, 05:42 UTC

Ergebnisse

Novartis Raises Profit Guidance as Key Drugs Boost Sales

9. Sept. 2024, 07:56 UTC

Market Talk

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

3. Sept. 2024, 14:07 UTC

Market Talk

Novartis Has a Strong Drug Pipeline But Investor Optimism Is Yet to Grow -- Market Talk

19. Aug. 2024, 13:36 UTC

Market Talk

Novartis Well on Track to Achieve Guidance -- Market Talk

14. Aug. 2024, 09:02 UTC

Market Talk

Novartis Could Slash Guidance Amid Generic Heart-Drug Competition -- Market Talk

18. Juli 2024, 11:55 UTC

Ergebnisse

Novartis Reports Near 40% Margin In Q2; Shares Slide -- IBD

18. Juli 2024, 09:40 UTC

Market Talk

Ergebnisse

Novartis 2Q Results Seem Solid, Catalysts in Focus -- Market Talk

18. Juli 2024, 08:45 UTC

Market Talk

Ergebnisse

Novartis Sales Beat Reflects Demand for New Drugs, Older Blockbusters Lag -- Market Talk

18. Juli 2024, 07:48 UTC

Market Talk

Novartis Prostate-Cancer Drug Pluvicto Sales Miss Raises Growth Questions -- Market Talk

18. Juli 2024, 07:01 UTC

Market Talk

Ergebnisse

Novartis Profit Outlook Lift Reflects Blockbuster Drug Sales Boost, Operational Execution -- Market Talk

18. Juli 2024, 05:18 UTC

Ergebnisse

Correct: Novartis 2Q Core Operating Profit $4.95B

18. Juli 2024, 05:03 UTC

Ergebnisse

Novartis Had Seen Net Sales to Grow High-Single to Low Double-digit in 2024

18. Juli 2024, 05:03 UTC

Ergebnisse

Novartis Net Sales Guidance in 2024 Unchanged

18. Juli 2024, 05:03 UTC

Ergebnisse

Novartis Had Seen Core Operating Income to Grow Low Double-Digit to Mid-Teens in 2024

18. Juli 2024, 05:03 UTC

Ergebnisse

Novartis Expects Core Operating Income to Grow Mid- to High Teens in 2024

18. Juli 2024, 05:02 UTC

Ergebnisse

Novartis Raises 2024 Guidance

18. Juli 2024, 05:01 UTC

Ergebnisse

Analysts Had 2Q Core Operating Profit at $4.67B

18. Juli 2024, 05:01 UTC

Ergebnisse

Analysts Had 2Q Sales at $12.22B

18. Juli 2024, 05:01 UTC

Ergebnisse

Novartis 2Q Sales $12.51B

18. Juli 2024, 05:01 UTC

Ergebnisse

Novartis 2Q Core Operating Profit $12.51B

18. Juli 2024, 05:00 UTC

Ergebnisse

Novartis AG 2Q EPS $1.60

18. Juli 2024, 05:00 UTC

Ergebnisse

Novartis AG 2Q Adj EPS $1.97

18. Juli 2024, 05:00 UTC

Ergebnisse

Novartis AG 2Q Net Pft $3.2B

20. Juni 2024, 06:35 UTC

Akquisitionen, Fusionen, Übernahmen

MorphoSys Delisting From Frankfurt Stock Exchange, Nasdaq Expected to Take Place in 3Q

20. Juni 2024, 06:34 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis Delisting Offer Is In Line With Price of Acquisition Closed in May

20. Juni 2024, 06:33 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis to Offer EUR68 a Share in Cash to Minority MorphoSys Shareholders

20. Juni 2024, 06:32 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis Holds Around 91.04% of MorphoSys as of Thursday

20. Juni 2024, 06:31 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis to Start Squeeze-Out of MorphoSys' Minority Shareholders

Peer-Vergleich

Kursveränderung

Novartis AG Prognose

Kursziel

By TipRanks

2.96% Vorteil

12-Monats-Prognose

Durchschnitt 119.08 USD 2.96%

Hoch 130 USD

Tief 97 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Novartis AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Novartis AG – Dist abgegeben haben.

Technischer Score

By Trading Central

115.28 / 117.16Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Novartis AG

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.